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Abstract: Background: Impella CP is a left ventricular pump which may serve as a circulatory
support during cardiopulmonary resuscitation (CPR) for cardiac arrest (CA). Nevertheless, the
survival rate and factors associated with survival in patients undergoing Impella insertion during
CPR for CA are unknown. Methods: We performed a retrospective multicenter international registry
of patients undergoing Impella insertion during on-going CPR for in- or out-of-hospital CA. We
recorded immediate and 30-day survival with and without neurologic impairment using the cerebral
performance category score and evaluated the factors associated with survival. Results: Thirty-five
patients had an Impella CP implanted during CPR for CA. Refractory ventricular arrhythmias were
the most frequent initial rhythm (65.7%). In total, 65.7% of patients immediately survived. At 30 days,
45.7% of patients were still alive. The 30-day survival rate without neurological impairment was
37.1%. In univariate analysis, survival was associated with both an age < 75 years and a time from
arrest to CPR ≤ 5 min (p = 0.035 and p = 0.008, respectively). Conclusions: In our multicenter registry,
Impella CP insertion during ongoing CPR for CA was associated with a 37.1% rate of 30-day survival
without neurological impairment. The factors associated with survival were a young age and a time
from arrest to CPR ≤ 5 min.
Keywords: Impella; cardiac arrest; refractory cardiac arrest; hemodynamic support device; cardiopulmonary resuscitation
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1. Introduction
Sudden cardiac arrest (CA) is a major cause of death worldwide [1]. Survival following
cardiopulmonary resuscitation (CPR) remains limited and the overall rate of survival to
hospital discharge is about 10% for both in-hospital and out-of-hospital CA [2–5]. Despite
advances in CPR, survival remains limited [6]. Following reports of a benefit of extracorporeal membrane oxygenation (ECMO) in patients with refractory CA, mechanical circulatory
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support (MCS) has emerged as a tool of potential interest [4,7]. Standardized protocols to
better select patients who may benefit from ECMO and prevent futile use were proposed
in the most recent guidelines [4,8]. Although ECMO support is associated with improved
survival in selected patients, it is a resource-intensive therapy requiring a dedicated staff
and therefore has a limited availability in centers without on-site ECMO [9,10]. The Impella
CP device is a continuous flow pump inserted percutaneously into the left ventricle (LV),
ensuring up to 3.5 L of blood flow per minute [11]. This device is available in cath-labs and
could be quickly implemented during CPR. In recent years, case reports and monocenter
registries have suggested a potential role for Impella CP in the setting of CA [12–14]. However, in these reports, the inclusion criteria and survival rates were variable, the sample
size was limited, and predictors of success could not be determined. We therefore initiated
an international multicenter registry of Impella implantation during on-going CPR for CA
related to acute coronary syndrome (ACS), in order to investigate the outcome and the
factors associated with survival.
2. Experimental Section
2.1. Participants and Informed Consent
The Impella CP registry is a retrospective multicenter registry from April 2014 to
January 2020 of 35 patients who required Impella CP (Abiomed, Inc., Danvers, MA, USA)
implantation during on-going CPR with manual or mechanical chest compression for CA
presumably related to an ACS based on electrocardiography (ECG) and clinical features
(ST segment elevation on ECG, shockable initial rhythm, or chest pain prior to the cardiac
arrest). Only patients who had continuous on-going CPR when the Impella device was
inserted were included. Patients with both in- or out-of-hospital witnessed CA were eligible. In out of hospital cardiac arrest (OHCA) situations, patients were transferred during
ongoing CPR in hospital. If return of spontaneous circulation (ROSC) and hemodynamic
stability were obtained before the Impella device was implanted and started pumping,
cardiac arrest was not considered refractory and the patient was not included [4]. Patients
without ongoing CA presenting with hemodynamic instability due to cardiogenic shock
were not included in the analysis. The present retrospective registry conformed to the ethical guidelines of the 1975 Declaration of Helsinki and received institutional review board
approval, and informed written consent was obtained from each patient before hospital
discharge. When the patient was deceased, the consent was obtained from the family.
2.2. Study Procedure
The device was inserted during CPR in the catheterization laboratory via the femoral
artery under vascular ultrasound guidance when possible and as specified by the manufacturer. Coronary angiography was conducted in all patients after Impella insertion and start.
If required, revascularization was performed, depending on the clinical context. Chest
compressions were continued until sufficient Impella flow could be achieved or until the
patients was considered deceased. The neurological status was assessed using the cerebral
performance category score (CPC score) collected from the medical health records. The
weaning of the hemodynamic support was conducted according to each center’s protocols.
Clinical data and survival at one month were collected retrospectively from electronic
medical records in a dedicated database. Vascular complications were all complications
requiring surgical care (including access site infection). Bleeding complications include all
bleeding requiring transfusion. Time from arrest to CPR was defined as the time between
collapse and the beginning of CPR (also called the “no flow time”). The CPR duration
was the time of continuous manual or mechanical chest compressions (also called the
“low flow time”). If a sustained and continuous ROSC (>30 min) was achieved, CA was
not considered refractory and the patient was not eligible. When many short periods of
unsustained ROSC were achieved, this time was deduced from the CPR duration.
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2.3. Statistical Analysis
Statistical analyses were performed using IBM SPSS Statistics 20.0 (IBM Inc., New York,
NY, USA). Continuous data are reported as the mean ± standard deviation. Categorical
data are reported as absolute counts (percentages). Continuous data were compared using
a Mann–Whitney test. Categorical data were compared using an χ2 test or a Fisher’s exact
test. The Kaplan–Meier method was used to describe the probability of survival over time
in the whole population. All tests were two-sided. Differences were considered to be
statistically significant when the p value was less than 0.05. Figures were drawn using the
GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA) software system.
3. Results
The registry included 35 patients from five different tertiary centers in four different
countries, including the USA, Denmark, France, and The Netherlands, requiring ongoing
CPR for CA.
3.1. Patients’ Characteristics
The main characteristics of the study population are described in Table 1. Patients
had a mean age of 66 ± 9 years and the majority had suffered in-hospital CA (80.6%).
The cardiac rhythm at the time of CA was a refractory ventricular arrhythmia in 65.7% of
patients. The mean time from arrest to CPR was 3 ± 4 min. The mean time from CA to
implantation of the Impella CP device and the delivery of blood flow was 46 ± 33 min.
The duration of CPR for intra-hospital cardiac arrest (IHCA) patients was 39 ± 32 min,
whereas the time of CPR for OHCA patients was 75 ± 40 min (p = 0.04). In all patients, an
Impella CP device was used. The mean first in-hospital arterial pH and lactate levels were
7.0 ± 0.1 and 11.8 ± 3.8 mmol/L, respectively. Extended CPR was required following Impella
start in 48.6% of patients. Coronary revascularization was performed in 85.7% of patients
after device implantation. Four patients needed ECMO support after Impella insertion.
Table 1. Characteristics of the population.
Variables

Entire Population (n = 35)

Age (years)

66 ± 9/65 (59–72)

Male

28 (80.0)
Location of cardiac arrest

IHCA

29 (80.6)

OHCA

6 (17.1)
Initial rhythm

VF/VT

23 (65.7)

PEA/asystole

12 (34.3)
CPR time courses

Time from arrest to CPR (min)

3 ± 4/0 (0–5)

CPR duration (min)

45 ± 36/30 (20–55)

Time between CA and Impella insertion (min)

46 ± 33/35 (26–60)

Extended CPR after Impella insertion

17 (48.6)

Initial blood gas
Lactates

11 ± 3.8

Arterial pH

7.0 ± 0.1
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Table 1. Cont.
Variables

Use of catecholamines
Use of catecholamines
Adrenaline
Adrenaline
Dobutamine
Dobutamine
Noradrenaline
Noradrenaline
Duration
of Impella support (hours)
Duration
of inotropic
Duration
of Impella
supportsupport
(hours) (hours)
Outcomes
Duration of inotropic support (hours)
Median hospital length of stay (days)
mean ± SD
Outcomes
Vascular
complications
Median hospital length of stay (days) mean ± SD
Immediate survival
Vascular complications
Survival at 1-month

Entire Population (n = 35)

23 (65.7)
12 (34.3)
12 (34.3)
23 (65.7)
23 (65.7)
43.1
± 48/24 (1–72)
± 238.8/45
43.1151
± 48/24
(1–72) (1–200)
23 (65.7)

151 ± 238.8/45 (1–200)

17 ± 20/11 (1–26)
6 (17.1)
17 ± 20/11 (1–26)
23 (65.7)
6 (17.1)
16 (45.7)

Immediate survival
23 (65.7)
Values are the mean ± SD/median (IQR) for continuous data or n (%). Legend: CA: cardiac arrest;
Survival
at 1-month IHCA: intra-hospital cardiac arrest;
16OHCA:
(45.7) out-of-hospital
CPR: cardiopulmonary
resuscitation;
cardiacarearrest;
PEA:± pulseless
electrical
VF:data
ventricular
and
VT: arrest;
ventricular
Values
the mean
SD/median
(IQR) foractivity;
continuous
or n (%). fibrillation;
Legend: CA:
cardiac
CPR:
tachycardia.
cardiopulmonary
resuscitation; IHCA: intra-hospital cardiac arrest; OHCA: out-of-hospital cardiac arrest; PEA:
pulseless electrical activity; VF: ventricular fibrillation; and VT: ventricular tachycardia.

3.2. Outcome
3.2. Outcome
Twelve patients (34.3%) died in the cath-lab and 23 (65.7%) survived the procedure
and were
transported
to the intensive
carecath-lab
unit. Following
the procedure,
allthe
patients
were
Twelve
patients (34.3%)
died in the
and 23 (65.7%)
survived
procedure
and
were
transported to(Table
the intensive
unit.
Followinglength
the procedure,
all patients
under
catecholamines
1). Thecare
mean
in-hospital
of stay was
17 ± 20 were
days
under
catecholamines
(Table At
1). 30-day
The mean
in-hospital
length (45.7%)
of stay were
was 17
± 20
days
(median
11 days IQR (1–26)).
follow-up,
16 patients
alive
(Figure
(median
days IQR
Atsurvivors
30-day follow-up,
16had
patients
(45.7%) were
alive(CPC
(Figure
1).
1). Three11
patients
out(1–26)).
of the 16
at 30-days
neurological
sequelae
score
Three
patients the
out 30-day
of the 16
survivors
at without
30-days had
neurological
sequelae
(CPC
score
> 2).
> 2). Overall,
survival
rate
neurological
sequelae
(CPC
score
1 or
2)
Overall,
the 30-day
survival
rate without
neurological
sequelae
(CPC scoreCA
1 orin2)all
was
37.1%.
was 37.1%.
The cause
of death
was multi
organ failure
or refractory
patients.
The
cause and
of death
was multi
organ failure
or refractory
in all (17.1%),
patients. ofVascular
Vascular
bleeding
complications
occurred
in six CA
patients
which and
two
bleeding
complications
occurred
in
six
patients
(17.1%),
of
which
two
required
vascular
required vascular surgery, but none led to death. When considering survival surgery,
at each
but
none
led
to death.
When considering
survival between
at each center,
we found
a non-significant
center,
we
found
a non-significant
heterogeneity
participating
hospitals
(I² = 43%,
heterogeneity
between
participating
hospitals (I2 = 43%, p = 0.149, Figure S1).
p = 0.149, Online
Figure
1).

Figure 1. Kaplan–Meier curve showing the probability of survival over time.

Figure 1. Kaplan–Meier curve showing the probability of survival over time.

3.3. Factors Associated with Immediate and 30-Day Survival
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3.3. Factors Associated with Immediate and 30-Day Survival
As illustrated in Table 2, patients who survived the procedure were significantly
younger (p = 0.02) and displayed a short time between CA and the initiation of CPR
(p < 0.01). Although it did not reach statistical significance, there was a strong association
between immediate survival and the presence of an initial shockable rhythm compared to
pulseless electric activity or asystole (p = 0.059). Revascularization was not associated with
immediate survival (p = 0.57). Regarding 30-day survival, we observed no difference in
survival between in- and out-of-hospital CA (p = 0.99) (Figure 2). We observed a significant
association between age and 30-day survival (p = 0.035). Among the seven patients over
75 years old, none survived to 30 days (Figure 3). The time between CA and CPR was
also a factor associated with survival (p = 0.008) (Figure 4). Patients with a time from CA
to CRP > 5 min did not survive. Again, although not significant, a trend toward a better
30-day survival was observed in patients with an initial shockable rhythm (p = 0.076).
Table 2. Univariate predictors of survival.
Successful Resuscitation n, (%)

Deceased Patients (n = 12)

Survivors (n = 23)

p

Age and mean ± SD
VF/VT
Time from arrest to CPR (min)
pH at initiation of CPR
Lactates level at initiation of CPR (mmol/L)

71 ± 7
5 (41.7)
6±5
7.0
12.2

63 ± 9
18 (78.3)
1±2
7.02
10.6

0.023
0.059
0.01
0.487
0.333

1-month n, (%)

Deceased Patients (n = 19)

Survivors (n = 16)

p

Age y mean ± SD
VF/VT
Time from arrest to CPR (min)
pH at initiation of CPR
Lactates level at initiation of CPR (mmol/L)

69 ± 8
10 (52.6)
4±4
7.04
10.8

62 ± 9
13 (81.2)
1±2
6.98
11.3

0.035
0.076
0.008
0.298
0.696

Values are the mean ± SD or n (%). Legend: VF: ventricular fibrillation, and VT: ventricular tachycardia.

Figure 2. Relationship between the cardiac arrest location and 1-month survival (p value [Fisher’s
exact test] = 0.999).
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Figure 3. Relationship between age and 30-day survival.

Figure 4. Scatter plot of time from arrest to cardiopulmonary resuscitation (CPR) (no flow time) in
survivors and non survivors at 1 month (p value [Mann–Whitney] = 0.008).

4. Discussion
The Impella CP registry suggests that the early implantation of an Impella CP during
ongoing-CPR for CA related to ACS is feasible and is associated with a 30-day survival
rate of 45.7% and 37.1% without neurological sequelae. Previous monocenter studies
have suggested that such an intervention could be successful. However, they had various
inclusion criteria, involved a small sample size, and reported a large survival rate ranging
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between 5% and 50% [14,15]. The relatively high survival rate reported in our study was
obtained despite the fact that the Impella was inserted as a salvage therapy during ongoing
CPR without ROSC. However, because of the retrospective nature of the study and small
sample size, these results should be considered preliminary and considered as a feasibility
and safety analysis.
Although Impella is only an LV support device, it enabled successful resuscitation
in a significant number of patients with ongoing CPR for CA. The feasibility and efficacy
of only supporting the LV, with the Impella CP, during resuscitation in the present study
are consistent with recent experimental and clinical evidence. Lotun et al. were able
to resuscitate swine specimens in CA thanks to the combination of chest compressions
and Impella, with favorable neurological recovery [16]. In their experimental model,
the survival rate of Impella-facilitated resuscitation was superior to conventional CPR.
Furthermore, in humans, consistent with our findings, previous reports have underlined
the feasibility of LV support with only the Impella in CA [12–15].
In our study, the 1-month survival rate was 45.7% and 37.1% without neurological
impairment. These results, although based on a limited number of patients, are promising
and similar to those obtained with ECMO [17,18]. To date, few therapies have improved the
outcome of CA [19]. ECMO is currently used in refractory CA based on promising registry
data. Although there are no randomized studies, meta-analysis has suggested that ECMO
utilization results in an overall survival rate of 22%, including 13% of patients with a good
neurological recovery in refractory CA [7]. Furthermore, in another meta-analysis, ECMO
was associated with a 13% absolute increase in 30-day survival compared to standard
CPR [20]. However, the selection of patients is key, as demonstrated by the lack of overall
benefit of ECMO compared to standard CPR in a propensity match analysis [21]. Lamhaut
et al. reported that the appropriate selection of patients with CA for MCS is critical to
preventing futile use [22]. Overall, these studies are in favor of a benefit of MCS in CA in
selected patients. Accordingly, despite the relatively small sample size of our study, we
were able to identify the duration of time from arrest to CPR and age as factors associated
with survival. This result is original, since previous studies with the Impella could not
assess factors associated with survival given their small sample size. Our findings are
consistent with previous observations with ECMO [23] regarding these predictors, which
are commonly used to select patients for MCS during CA [4]. Of note, our revascularization
rate is close to those observed in the same setting in the literature [24]. Although the
duration of CPR was not identified as a factor associated with survival in our study, it
is well-recognized that a sustained time of CPR is associated with a poor outcome [25].
The lack of a significant impact of the duration of CPR in our study is probably related
to the limited sample size. However, the factors associated with survival evidence in the
present registry are useful for accurately selecting patients for Impella CP insertion during
on-going CPR for CA and can help in the design of future trials in this field. Our results
suggest that the implantation of Impella in patients over 75 years old or with a time from
arrest to CPR > 5 min in the setting of ongoing CPR for CA may be futile.
In the setting of refractory CA, there are potential advantages of the Impella device
over ECMO. First, Impella seems more available and quicker to insert by the interventional
cardiologist than ECMO, which may ensure greater access to MCS for patients [26]. In
addition, it reduces the time to full hemodynamic support and CPR duration, which are
also critical for success in the setting of CA. Therefore, the Impella device may play a role in
centers without ECMO or when the time to ECMO is expected to be long. Furthermore, the
use of the Impella device may result in a lower rate of device-related vascular complications
compared to ECMO [26,27]. Finally, ECMO-generated blood flow is continuous and
retrograde, increasing ventricular stroke work and making this system efficient in terms of
supporting peripheral organs, but responsible for LV overload [28,29]. On the other hand,
Impella, despite a lower blood flow, is associated with several favorable properties of the
heart by unloading the LV, limiting the infarct size, and promoting recovery [30]. However,
there are no studies comparing ECMO and Impella in CA.
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Limitations
There are limitations to the present findings. First, the sample size is small, which may
limit the generalizability of our results and prevented multivariate analysis for predictors of
survival. Second, there is an obvious selective bias when using such an invasive and costly
strategy for specific patients who may be considered as having a higher chance of survival
and lower co-morbidities. Third, the majority of reported cases had good prognosis factors,
such as in-hospital cardiac arrest and a limited period of time from arrest to CPR, and
our result may not apply in a larger population. Additionally, the number of patients
suffering OHCA is rather small and their time of CPR was longer than IHCA. Fourth, this
is a retrospective observational study with inherent limitations and some clinical data were
not available.
Nevertheless, the present study is the largest to date and suggests that in selected
patients, Impella CP may be a lifesaving tool during CPR for CA related to an ACS.
Prospective and larger studies are required to confirm these preliminary results, perform
multivariate analysis for obtaining more reliable results, and help better define the patients
likely to benefit from biventricular support rather than LV support alone during CPR for
CA related to ACS.
5. Conclusions
In this international registry, in patients undergoing Impella CP insertion during
on-going CPR for CA, the 30-day survival rate was 45.7% overall and 37.1% without
neurological impairment. Impella CP insertion may be lifesaving in patients with CA
younger than 75 years old with a time from arrest to CPR ≤ 5 min. Prospective studies are
required to confirm these encouraging but preliminary data and should help to accurately
define patient selection criteria.
Supplementary Materials: The following are available online at https://www.mdpi.com/2077-038
3/10/2/339/s1, Figure S1: Hetereogeneity between participating centers.
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